[go: up one dir, main page]

PE20181066A1 - Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos - Google Patents

Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos

Info

Publication number
PE20181066A1
PE20181066A1 PE2018000249A PE2018000249A PE20181066A1 PE 20181066 A1 PE20181066 A1 PE 20181066A1 PE 2018000249 A PE2018000249 A PE 2018000249A PE 2018000249 A PE2018000249 A PE 2018000249A PE 20181066 A1 PE20181066 A1 PE 20181066A1
Authority
PE
Peru
Prior art keywords
monovalent
polypeptides
chain
diacbody
seq
Prior art date
Application number
PE2018000249A
Other languages
English (en)
Inventor
Leslie S Johnson
Paul A Moore
Ezio Bonvini
Ling Huang
Kalpana Shah
Ralph Alderson
Gurunadh Reddy Chichili
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of PE20181066A1 publication Critical patent/PE20181066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN DIACUERPO FC MONOVALENTE BIESPECIFICO DE B7-H3 X CD3 QUE SE UNE ESPECIFICAMENTE A B7-H3 Y A CD3, DONDE EL DIACUERPO COMPRENDE UNA PRIMERA, UNA SEGUNDA Y UNA TERCERA CADENA DE POLIPEPTIDOS QUE FORMAN UN COMPLEJO ENLAZADO DE FORMA COVALENTE, EN DONDE A) LA PRIMERA CADENA DE POLIPEPTIDOS TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 53, 59, 61 O 63; B) LA SEGUNDA CADENA DE POLIPEPTIDOS TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 55, 60, 62 O 64; Y C) LA TERCERA CADENA DE POLIPEPTIDOS TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 57. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO DIACUERPO FC MONOVALENTE BIESPECIFICO DE B7-H3 X CD3, EL CUAL ES UTIL EN EL TRATAMIENTO DE CANCER DE VEJIGA, CANCER DE MAMA, CANCER DE COLON
PE2018000249A 2015-08-17 2016-08-12 Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos PE20181066A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
PE20181066A1 true PE20181066A1 (es) 2018-07-04

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000249A PE20181066A1 (es) 2015-08-17 2016-08-12 Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos

Country Status (21)

Country Link
US (1) US20190002563A1 (es)
EP (1) EP3337507A4 (es)
JP (1) JP2018523686A (es)
KR (1) KR20180038045A (es)
CN (1) CN107921130A (es)
AU (1) AU2016307955A1 (es)
CA (1) CA2995709A1 (es)
CL (1) CL2018000422A1 (es)
CO (1) CO2018001485A2 (es)
CR (1) CR20180105A (es)
EA (1) EA201890443A1 (es)
EC (1) ECSP18011248A (es)
HK (1) HK1249423A1 (es)
IL (1) IL257562A (es)
MA (1) MA42665A (es)
MX (1) MX2018001954A (es)
PE (1) PE20181066A1 (es)
PH (1) PH12018500363A1 (es)
TW (1) TW201718652A (es)
WO (1) WO2017030926A1 (es)
ZA (1) ZA201800955B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2890079T3 (es) * 2014-05-29 2022-01-17 Macrogenics Inc Moléculas de unión triespecíficas y métodos de uso de las mismas
UY36316A (es) 2014-09-26 2016-04-29 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
WO2017106061A1 (en) 2015-12-14 2017-06-22 Macrogenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
EP4628164A2 (en) * 2017-09-08 2025-10-08 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
CA3096123A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
JP2022512684A (ja) 2018-10-11 2022-02-07 インヒブルクス インコーポレイテッド Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
CN113166262B (zh) 2018-10-11 2025-10-17 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
KR20210100654A (ko) * 2018-12-07 2021-08-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd3 항체 및 그의 약제학적 용도
CN112969476B (zh) * 2018-12-07 2024-06-14 江苏恒瑞医药股份有限公司 多特异性蛋白分子
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
AU2020412595A1 (en) * 2019-12-23 2022-07-14 Macrogenics, Inc. Therapy for the treatment of cancer
MX2022009306A (es) 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
CN117751145A (zh) * 2021-04-28 2024-03-22 礼进生物医药科技（上海）有限公司 包括抗b7h3结合分子的双特异性抗体
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03447B (me) * 2010-03-04 2020-01-20 Macrogenics Inc Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
ES2732213T3 (es) * 2011-05-21 2019-11-21 Macrogenics Inc Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CN108136010A (zh) * 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法

Also Published As

Publication number Publication date
AU2016307955A1 (en) 2018-03-08
EA201890443A1 (ru) 2018-09-28
ZA201800955B (en) 2018-11-28
KR20180038045A (ko) 2018-04-13
MA42665A (fr) 2018-06-27
CL2018000422A1 (es) 2018-08-10
US20190002563A1 (en) 2019-01-03
EP3337507A4 (en) 2019-04-24
CR20180105A (es) 2018-06-12
PH12018500363A1 (en) 2018-09-10
HK1249423A1 (zh) 2018-11-02
CN107921130A (zh) 2018-04-17
JP2018523686A (ja) 2018-08-23
CA2995709A1 (en) 2017-02-23
IL257562A (en) 2018-04-30
ECSP18011248A (es) 2018-04-30
TW201718652A (zh) 2017-06-01
CO2018001485A2 (es) 2018-07-10
EP3337507A1 (en) 2018-06-27
MX2018001954A (es) 2018-11-09
WO2017030926A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
PE20181066A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20170286A1 (es) Diacuerpos heterodimericos biespecificos y sus usos
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
PE20150605A1 (es) Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
UY36289A (es) ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN
MX2017006966A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PE20190737A1 (es) Anticuerpos anti-cd27
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
AR106555A1 (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
HK1249048A1 (zh) 靶向afp肽/mhc复合体的构建体及其用途
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX384418B (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer